Experimental assessment of the addiction liability of N-(y-aminobutyryl)-1-aza-4,7,10,13-tetraoxacyclopentadecane hydrochloride (C-3) in rats
Open Access
- 18 March 2026
- journal article
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Vinnytsia National Medical University
- Vol. 30 (1) , 42-47
Abstract
The safe clinical use of centrally acting analgesics remains limited by the risk of tolerance, physical dependence, and addictive behavior associated with prolonged administration. Therefore, preclinical evaluation of abuse liability represents an essential component of pharmacological screening for novel analgesic compounds. The aim of this study was to experimentally assess the addictive potential of compound C-3 (N-(γ-aminobutyryl)-1-aza-4,7,10,13-tetraoxacyclopentadecane hydrochloride) by investigating reward-related behavior, tolerance development, cross-tolerance, and withdrawal manifestations in rats. The study was conducted in adult male Wistar rats (n = 7 per group). Reward properties were evaluated using the conditioned place preference (CPP) paradigm. Antinociceptive effect and tolerance were assessed in the tail-flick test following 28-day intraperitoneal administration of C-3 (1 mg/kg), while cross-tolerance was examined after morphine administration (5 mg/kg). Statistical analysis was performed using nonparametric tests (Mann–Whitney U test, Wilcoxon signed-rank test, Friedman test; p<0.05). C-3 produced a significant antinociceptive effect, increasing latency by 58.9% compared with baseline values (p0.05). Discontinuation of chronic treatment did not induce hyperalgesia or clinically relevant signs of spontaneous withdrawal. Moreover, morphine responsiveness remained preserved after prolonged C-3 exposure, demonstrating absence of cross-tolerance and suggesting lack of long-term μ-opioid receptor desensitization. Collectively, these findings indicate a favorable addiction-related profile of C-3 under the studied dosing regimen. Further investigations should explore broader dose ranges and clarify receptor-mediated mechanisms underlying its pharmacological effects.Keywords
This publication has 19 references indexed in Scilit:
- Conditioned place preference with low dose mixtures of α-pyrrolidinopentiophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley ratsPharmacology Biochemistry and Behavior, 2024
- Preclinical evaluation of abuse potential of the peripherally-restricted kappa opioid receptor agonist HSK21542Regulatory Toxicology and Pharmacology, 2024
- Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment optionsPharmacology Biochemistry and Behavior, 2024
- Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisisBJA Open, 2023
- Macrocycles in Drug Discovery─Learning from the Past for the FutureJournal of Medicinal Chemistry, 2023
- Evaluating pain behaviours: Widely used mechanical and thermal methods in rodentsBehavioural Brain Research, 2023
- Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studiesNeuropsychopharmacology, 2022
- The changing opioid crisis: development, challenges and opportunitiesMolecular Psychiatry, 2020
- Translational Molecular Approaches in Substance Abuse Research2019
- An Overview of Animal Models of Pain: Disease Models and Outcome MeasuresThe Journal of Pain, 2013